Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy in China: A Multicenter, Prospective Cohort Study

This study is a multicenter, prospective, cohort study designed to evaluate the clinical outcomes and characteristics of resected stage II-IIIB anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) adult patients treated with Alectinib as adjuvant therapy in China.

开始日期2025-03-26

申办/合作机构

Hoffmann-La Roche Ltd.

NCT06692491

/ Not yet recruiting临床2期IIT

A Phase II Clinical Study on Precision Treatment of Rare Tumours in China Guided by Patient-Derived Tumor Organoids (PDO) and Next-Generation Sequencing (NGS)

The objective of this Phase II, open-label, multicenter, non-randomised controlled clinical trial is to guide precision treatment for patients with rare tumours based on Patient-Derived Organoids/Next-Generation Sequencing drug screening.

开始日期2025-01-01

申办/合作机构

北京大学深圳医院（北京大学深圳临床医学院）

CTR20243865

/ Recruiting临床1期

一项在根据生物标志物状态选择的可切除I-III期非小细胞肺癌患者队列中评价多种治疗有效性和安全性的多中心I-III期研究

本研究旨在评价多种治疗在早期可切除NSCLC患者中的有效性和/或安全性。队列B1：评价阿来替尼联合化疗在完全切除的II期、IIIA期和选定的IIIB期（仅T3N2；根据AJCC第8版）、ALK阳性NSCLC患者中的安全性；队列B2：在可切除的II、IIIA和选定IIIB期（仅T3N2；根据AJCC第8版）ALK阳性NSCLC患者中评价阿来替尼联合化疗新辅助治疗的有效性

开始日期2024-12-30

申办/合作机构

F. Hoffmann-La Roche Ltd.

[+1]

100 项与盐酸阿来替尼相关的临床结果

登录后查看更多信息

100 项与盐酸阿来替尼相关的转化医学

登录后查看更多信息

100 项与盐酸阿来替尼相关的专利（医药）

登录后查看更多信息

1,708

项与盐酸阿来替尼相关的文献（医药）

2025-12-31·Hospital practice (1995)

Unraveling the unforeseen: anuric acute kidney injury induced by alectinib

Article

作者: Taha, Amro ; Ali, Shehzad ; Nguyen, Chau Doan ; Qadeer, Tahira ; Tran, Viet Nghi ; Kebato, Yusuf Hussein

INTRODUCTION:

Alectinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor, is pivotal in managing ALK-positive non-small cell lung cancer (NSCLC) due to its efficacy and favorable safety profile. However, severe renal toxicity, including acute kidney injury (AKI), remains a rare but significant adverse effect.

CASE REPORT:

We present the case of a 71-year-old female with a history of diabetes and recently diagnosed ALK-positive NSCLC. She had been on alectinib therapy (600 mg twice daily) for two months. The patient was admitted with symptoms of shortness of breath and anuria. Initial laboratory results revealed a significant rise in serum creatinine from a baseline of 1.0 mg/dL to 3.64 mg/dL, indicating AKI. Alectinib was discontinued, and the patient underwent a single session of hemodialysis. The patient exhibited rapid clinical improvement with significant recovery of renal function, and she was discharged without the need for further dialysis. A subsequent switch to brigatinib was well-tolerated, with stable renal function observed at the 4-month follow-up.

CONCLUSION:

This case underscores the potential for severe AKI associated with alectinib therapy, highlighting the importance of vigilant renal function monitoring in patients undergoing treatment, especially those with predisposing conditions. Early recognition and prompt intervention are crucial to mitigate renal complications and optimize patient outcomes. Brigatinib may serve as a suitable alternative for patients intolerant to alectinib.

2025-12-01·LUNG

Update 2025: Management of Non‑Small-Cell Lung Cancer

Review

作者: Jeon, Hyein ; Wang, Shuai ; Gill, Harjot ; Song, Junmin ; Cheng, Haiying

Abstract:

Lung cancer remains the leading cause of cancer-related mortality worldwide. Since 2024, the non–small-cell lung cancer (NSCLC) landscape has undergone a transformative shift, driven by 11 FDA approvals. Recent advances in molecular profiling, targeted therapies, and immunotherapies have revolutionized NSCLC management, ushering in an era of personalized treatment with improved patient outcomes. The increased adoption of low-dose computed tomography (LDCT) for screening has enhanced early detection, enabling intervention at more curable stages. Molecular diagnostics now play a pivotal role in guiding treatment strategies, with actionable genomic alterations (AGAs) informing the use of EGFR, ALK, ROS1, KRAS, NRG1, and other targeted inhibitors in both early and advanced settings. For instance, targeted therapies are increasingly being integrated into early-stage management, with adjuvant osimertinib for EGFR-mutated NSCLC and alectinib for ALK-positive NSCLC demonstrating substantial survival benefits. Immunotherapy, particularly immune checkpoint inhibitors, has become a cornerstone of treatment for AGA-negative NSCLC, either as monotherapy or in combination with chemotherapy, and is increasingly being utilized in the perioperative setting. Furthermore, emerging therapies such as bispecific antibodies, antibody–drug conjugates (ADCs), and novel immunotherapeutic agents show promise in addressing resistance mechanisms and improving outcomes in advanced-stage disease. Although new challenges arise, the evolving NSCLC treatment paradigm continues to prioritize precision medicine, offering hope for prolonged survival and enhanced quality of life for patients.

2025-10-01·Anti-Cancer Agents in Medicinal Chemistry

Redefining Anthraquinone-based Anticancer Drug Design through Subtle Chemical Modifications

Article

作者: De, Utpal Chandra ; Mishra, Bijayashree ; Acharya, Pratap Chandra

Anthraquinones are well known for their wide spectrum of pharmacological properties. Anthraquinone antibiotics, such as doxorubicin, daunorubicin, epirubicin, and mitoxantrone, have long been used in the clinical management of various tumors. However, their use is limited due to their toxicity effects, especially cardiomyopathy, despite their pronounced therapeutic effects. In recent years, medicinal chemists have explored the possibility of modifying the anthraquinone ring appended with structurally diverse functionality in order to develop better chemotherapeutic agents with fewer adverse effects. The fused polycyclic structure of anthraquinone offers rigidity, planarity, and aromaticity, which helps in double helix DNA intercalation, disruption of G4 DNA, and inhibition of topoisomerase-II enzyme of cancer cells, making them suitable pharmacophore for anticancer drug discovery. Incorporation of suitable functional groups such as amino, hydroxyl, and their derivatives into anthraquinone rings can improve their interactions with biological targets involved in cancer progression. These subtle structural changes produce newer anthraquinone derivatives with improved anticancer properties, increased potency, selectivity, and reduced toxicity, and can overcome multi-drug resistance. On the other hand, the molecular hybrids of the anthraquinone derivatives have been reported to act on multiple targets in cancer cells, as seen in the case of clinical candidates like alectinib, midostaurin, tucatinib, belinostat, and dacinostat. Molecular hybrid has given a new direction for anticancer drug development, which can produce bifunctional drug candidates with reduced toxicity. This review summarizes different structural modifications that have been made to the anthraquinone ring in the last decade with the aim of bringing out potent yet toxicity-free anticancer agents.

329

项与盐酸阿来替尼相关的新闻（医药）

2025-05-28

·肿瘤界

2025 ASCO | 10余项中国研究入选！肺癌口头报告摘要标题一文速览

点击蓝字关注我们前言作为肿瘤学领域的国际盛会，ASCO年会每年都吸引着来自世界各地的顶尖学者、临床专家与科研团队，共同分享最新研究成果、探讨创新疗法、展望未来趋势。随着2025年ASCO年会完整日程的正式公布，全球肿瘤学界的目光再次聚焦于此。在此，本文特整理了本届ASCO大会中肺癌领域入选的Oral Abstract Session（口头报告专场）、Rapid Oral Abstract Session（快速口头报告专场）以及Clinical Science Symposium（临床科学研讨会）的研究，让我们先一睹为快！Oral Abstract Session口头报告专场摘要号：2004研究英文名称：A phase II study of asandeutertinib (TY-9591) in advanced NSCLC patients with EGFR-positive mutations and brain metastases.研究中文名称：asandeutertinib（TY-9591）在EGFR阳性突变和脑转移的晚期NSCLC患者中的II期研究讲者：邢力刚 | 中国医学科学院肿瘤医院摘要号：3001研究英文名称：Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations.研究中文名称：BL-B01D1（iza-bren）治疗携带经典EGFR突变以外驱动基因改变的局部晚期或转移性NSCLC的I期临床研究：一种靶向EGFR×HER3的双特异特异性抗体驱动药物偶联物（ADC）的评估讲者：杨云鹏 | 中山大学肿瘤防治中心摘要号：3002研究英文名称：Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC).研究中文名称：iza-bren（BL-B01D1），一种EGFR x HER3双特异性ADC，在局部晚期或转移性小细胞肺癌（SCLC）患者中的I期研究讲者：黄岩 | 中山大学肿瘤防治中心摘要号：LBA8000研究英文名称：Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.研究中文名称：CheckMate 816研究中可切除NSCLC患者新辅助纳武利尤单抗联合化疗的总生存期分析讲者：Patrick M. Forde | Trinity St. James's Cancer Institute, Trinity College Dublin摘要号：8001研究英文名称：Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA.研究中文名称：NeoADAURA研究：可切除EGFR突变NSCLC术前新辅助奥希替尼±化疗对比单纯化疗讲者：Jamie E. Chaft | Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College摘要号：8002研究英文名称：Lung cancer diagnosis rates (LCDR) in lung cancer screening (LCS) and incidental pulmonary nodule (IPN) cohorts in the Mississippi Delta.研究中文名称：密西西比三角洲地区肺癌筛查与偶然发现肺结节队列中的肺癌诊断率研究讲者：Raymond U. Osarogiagbon | Baptist Cancer Center, Multidisciplinary Thoracic Oncology Program摘要号：8003研究英文名称：SWOG/NRG S1914: Randomized phase III trial of induction/consolidation atezolizumab + SBRT versus SBRT alone in high risk, early-stage NSCLC.研究中文名称：SWOG/NRG S1914研究：高危早期NSCLC诱导/巩固期阿替利珠单抗联合SBRT对比单纯SBRT的随机III期试验讲者：Megan Eileen Daly | Department of Radiation Oncology, University of California Davis Comprehensive Cancer Center摘要号：LBA8004研究英文名称：R-ALPS: A randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of TQB2450 with or without anlotinib as maintenance treatment in patients with locally advanced and unresectable (stage III) NSCLC without progression following concurrent or sequential chemoradiotherapy.研究中文名称：R-ALPS研究：贝莫苏拜单抗（TQB2450）联合或不联合安罗替尼维持治疗经同步或序贯放化疗后无进展的局部晚期不可切除（III期）NSCLC患者的随机、双盲、安慰剂对照、多中心III期临床试验讲者：陈明 | 中山大学肿瘤防治中心摘要号：LBA8005研究英文名称：Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC).研究中文名称：局限期小细胞肺癌（LS-SCLC）化放疗后使用阿替利珠单抗是否延长生存的随机II期试验讲者：Bjorn Henning Gronberg | Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology and Department of Oncology, St. Olavs Hospital摘要号：8006研究英文名称：Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.研究中文名称：III期IMforte研究：芦比替定联合阿替利珠单抗作为广泛期小细胞肺癌（ES‑SCLC）患者一线维持治疗的主要结果讲者：Luis G. Paz-Ares | Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc摘要号：8007研究英文名称：A phase 2 dose expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer.研究中文名称：ZG006（一种靶向CD3/DLL3/DLL3的三特异性T细胞接合器）单药治疗晚期SCLC的II期剂量扩展研究讲者：艾星浩 | 上海交通大学医学院附属胸科医院摘要号：LBA8008研究英文名称：Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304.研究中文名称：Tarlatamab对比化疗（CTx）二线（2L）治疗SCLC：III期DeLLphi-304研究的主要分析讲者：Charles M Rudin | Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center摘要号：8500研究英文名称：First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.研究中文名称：II期KRYSTAL‑7研究：adagrasib联合帕博利珠单抗一线治疗晚期/转移性KRASG12C突变NSCLC患者讲者：Pasi A. Jänne | Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute摘要号：8501研究英文名称：TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC).研究中文名称：TROPION‑Lung02研究：Dato-DXd联合帕博利珠单抗±铂类化疗一线治疗晚期NSCLC讲者：Benjamin Philip Levy | Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine摘要号：LBA8502研究英文名称：CAMPASS: Benmelstobart in combination with anlotinib vs pembrolizumab in the first-line treatment of advanced non-small cell lung cancer (aNSCLC): A randomized, single-blind, multicenter phase 3 study.研究中文名称：CAMPASS研究：贝莫苏拜单抗联合安罗替尼对比帕博利珠单抗一线治疗晚期NSCLC：一项随机、单盲、多中心III期研究讲者：韩宝惠 | 上海交通大学医学院附属胸科医院摘要号：8503研究英文名称：Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab.研究中文名称：zipalertinib对既往接受过含或不含埃万妥单抗铂类化疗的EGFR外显子20插入突变NSCLC患者的疗效评估讲者：Helena Alexandra Yu | Memorial Sloan Kettering Cancer Center摘要号：8504研究英文名称：SOHO-01: Safety and efficacy of BAY 2927088 in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) who were pretreated but naïve to HER2-targeted therapy or had not received any treatment for advanced disease.研究中文名称：SOHO-01研究：BAY 2927088治疗既往接受过治疗但未接受HER2靶向治疗或未接受过任何治疗的晚期HER2突变NSCLC患者的疗效和安全性研究讲者：Herbert H. Loong | 香港中文大学摘要号：LBA8505研究英文名称：Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.研究中文名称：赛沃替尼联合奥希替尼对比化疗治疗EGFR-TKI治疗进展后EGFR突变伴MET扩增的晚期NSCLC：来自III期随机SACHI研究结果讲者：陆舜 | 上海市胸科医院摘要号：8506研究英文名称：Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.研究中文名称：Patritumab-deruxtecan（HER3-DXd）治疗第三代EGFR-TKI治疗后耐药的EGFR突变晚期NSCLC：III期HERTHENA-Lung02研究讲者：莫树锦 | 香港中文大学摘要号：8507研究英文名称：Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study.研究中文名称：芦康沙妥珠单抗（sac-TMT）治疗既往接受过治疗的晚期EGFR突变NSCLC：来自OptiTROP-Lung03随机研究的结果讲者：张力 | 中山大学肿瘤防治中心Rapid Oral Abstract Session快速口头报告专场摘要号：8009研究英文名称：Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.研究中文名称：III期AEGEAN研究：术后MRD状态与新辅助ctDNA动态、基因突变特征及可切除NSCLC患者预后的相关性分析讲者：Martin Reck | Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research摘要号：LBA8010研究英文名称：Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: Updated survival and biomarker analyses from CheckMate 77T.研究中文名称：CheckMate 77T研究：可切除NSCLC患者围手术期纳武利尤单抗对比安慰剂治疗的生存及生物标志物更新分析讲者：Mariano Provencio | Hospital Universitario Puerta de Hierro摘要号：8011研究英文名称：ctDNA-based MRD detection in unresectable NSCLC undergoing curatively intended chemoradiotherapy and durvalumab.研究中文名称：在接受根治性放化疗及度伐利尤单抗治疗的不可切除NSCLC患者中基于ctDNA的MRD检测讲者：Aslaug Helland | University of Oslo, Clinical Medicine摘要号：8012研究英文名称：The preliminary results of a randomized phase II trial evaluating induction toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab in bulky unresectable stage III non-small-cell lung cancer (InTRist).研究中文名称：InTRist研究：评估特瑞普利单抗联合诱导化疗，随后同步放化疗及特瑞普利单抗巩固治疗用于巨大不可切除的III期NSCLC的随机II期试验的初步结果讲者：Yu Wang | 中国医学科学院肿瘤医院摘要号：8013研究英文名称：Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer: Results of the 2SMALL phase 1/2 study (NCT04253145).研究中文名称：I/II期2SMALL研究：芦比替定联合阿替利珠单抗作为晚期NSCLC二线治疗的疗效和安全性讲者：Santiago Ponce Aix | Hospital Universitario 12 de Octubre and Oncosur Foundation摘要号：8014研究英文名称：Clinical and molecular characteristics of early progressors (EPs) and long-term progression-free survivors (LTPs) from the phase 3 ADRIATIC trial of consolidation durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC).研究中文名称：III期ADRIATIC研究：同步放化疗后巩固度伐利尤单抗对比安慰剂治疗用于LS-SCLC患者中早期进展者与长期无进展生存者的临床与分子特征讲者：David Allen Barbie | Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute摘要号：8015研究英文名称：Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: Final analysis of ALNEO phase II trial (GOIRC-01-2020-ML42316).研究中文名称：阿来替尼作为新辅助治疗用于潜在可切除III期ALK阳性NSCLC的ALNEO II期研究最终分析（GOIRC-01-2020-ML42316）讲者：Marcello Tiseo | Department of Medicine and Surgery, University of Parma; Medical Oncology Unit, University Hospital of Parma; Gruppo Oncologico Italiano di Ricerca Clinica, GOIRC摘要号：8016研究英文名称：Efficacy and safety of nivolumab plus ipilimumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial.研究中文名称：纳武利尤单抗联合伊匹木单抗治疗经治的B3型胸腺瘤和胸腺癌患者的疗效与安全性：EORTC-ETOP NIVOTHYM II期研究结果讲者：Nicolas Girard, MD | Institut du Thorax Curie Montsouris, Institut Curie, Paris, and UVSQ, Paris Saclay University摘要号：8017研究英文名称：Integrin αVβ3-targeted imaging for identification of lung cancer and mapping of lymph-node metastases: A prospective, multicenter, self-controlled phase 3 trial (TRIIL study).研究中文名称：靶向整合素αVβ3的成像用于肺癌的识别和淋巴结转移的定位：一项前瞻性、多中心、自身对照的III期试验（TRIIL研究）讲者：Rongxi Wang | 北京协和医院摘要号：8512研究英文名称：Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced EGFR-mutated (MT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase 1 study.研究中文名称：靶向c-Met的抗体偶联药物（ADC）Telisotuzumab adizutecan（ABBV-400；Temab-A）治疗晚期EGFR突变非鳞NSCLC的I期研究结果讲者：David Ross Camidge | University of Colorado Cancer Center摘要号：8513研究英文名称：Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO).研究中文名称：II期SAVANNAH研究随机亚组结果：赛沃替尼联合奥希替尼对比赛沃替尼联合安慰剂的疗效及中枢神经系统结果分析讲者：Benjamin Philip Levy | Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine摘要号：8514研究英文名称：Phase 3 study of benmelstobart in combination with chemotherapy followed by sequential combination with anlotinib for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC).研究中文名称：贝莫苏拜单抗联合化疗，随后序贯联合安罗替尼一线治疗局部晚期或转移性鳞状NSCLC的III期研究讲者：石远凯 | 中国医学科学院肿瘤医院摘要号：8515研究英文名称：Plasma-guided adaptive first-line chemoimmunotherapy for non-small cell lung cancer (NSCLC).研究中文名称：血浆引导的NSCLC一线个体化化免治疗探索讲者：Julia K. Rotow | Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute摘要号：8516研究英文名称：Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer.研究中文名称：NSCLC患者免疫化疗时间与无进展生存期及总生存期相关性的随机试验讲者：张永昌 | 湖南省肿瘤医院摘要号：8517研究英文名称：Hypoxia-responsive CEA CAR-T cells therapy for relapsed or refractory non-small cell lung cancer: A single-arm, open-label, phase I trial.研究中文名称：缺氧反应型CEA CAR-T细胞疗法治疗复发或难治性NSCLC：一项单臂、开放标签、I期试验讲者：魏双 | 华中科技大学同济医学院附属同济医院摘要号：8518研究英文名称：S1900E: A phase II study examining impact of co-mutations on sotorasib for previously treated stage IV/recurrent KRAS G12C mutated (MUT) non-squamous (Non-sq) non-small cell lung cancer (NSCLC) (ECOG-ACRIN led Lung-MAP Sub-study).研究中文名称：S1900E研究：评估合并突变对sotorasib治疗经治的KRAS G12C突变IV期/复发性非鳞NSCLC疗效影响的II期研究（ECOG-ACRIN主导Lung-MAP子研究）讲者：Sukhmani Kaur Padda | Fox Chase Cancer Center/Temple Health摘要号：8519研究英文名称：Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with KRAS G12C-mutant advanced NSCLC: Update from the LOXO-RAS-20001 trial.研究中文名称：Olomorasib联合免疫治疗用于KRAS G12C突变晚期NSCLC一线治疗的疗效和安全性：LOXO-RAS-20001研究更新讲者：Konstantin H. Dragnev | Dartmouth Cancer Center摘要号：8520研究英文名称：Sosimerasib monotherapy in patients with previously treated KRAS G12C–mutated non-small cell lung cancer: Primary results of a phase 2 study.研究中文名称：Sosimerasib单药治疗KRAS G12C突变NSCLC：II期研究的主要结果讲者：王洁 | 中国医学科学院肿瘤医院摘要号：LBA8671研究英文名称：PRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.研究中文名称：Practicala-LUNG研究（SWOG S2302）：雷莫芦单抗联合帕博利珠单抗对比标准治疗用于既往接受过免疫治疗的IV期或复发性NSCLC患者的前瞻性随机研究讲者：Konstantin H. Dragnev | Dartmouth Cancer CenterClinical Science Symposium临床科学研讨会摘要号：8509研究英文名称：First-in-class PD-1/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC).研究中文名称：首创新药PD-1/IL-2双特异性抗体IBI363治疗经免疫治疗的晚期NSCLC患者讲者：周建娅 | 浙江大学医学院附属第一医院摘要号：8510研究英文名称：Efficacy and safety of MHB088C, a novel B7-H3-targeted ADC, in patients with relapsed extensive-stage small cell lung cancer (ES-SCLC): Subgroup analysis from a phase 1/2 multicenter study.研究中文名称：一项评估新型靶向B7-H3的ADCMHB088C治疗复发ES-SCLC的疗效与安全性的I/II期多中心研究的亚组分析讲者：周彩存 | 同济大学附属东方医院摘要号：8511研究英文名称：First report of efficacy and safety results from a phase 2 trial evaluating BNT327/PM8002 plus chemotherapy (chemo) as first-line treatment (1L) in unresectable malignant mesothelioma.研究中文名称：首个评估BNT327/PM8002联合化疗作为不可切除恶性胸膜间皮瘤一线治疗的II期试验的疗效及安全性结果报告讲者：程颖 | 吉林省肿瘤医院备注：如有遗漏或任何问题，请给我们留言~声明：本文由“肿瘤界”整理与汇编，欢迎分享转载，如需使用本文内容，请务必注明出处。来源：医脉通胸部肿瘤编辑：lagertha审核：南星

抗体药物偶联物临床结果ASCO会议临床1期

2025-05-22

·癌度

颠覆认知！癌细胞竟然会共享营养、协同抗药，我们如何应对？

癌度医学临床招募资讯微信群（点击）恶性肿瘤的本质是人体细胞基因突变导致的疾病，我们在关于肿瘤这个疾病常见误区是：“肿瘤病灶就在那里，它们是静止不动被动挨打的，只要第一时间用上药物就可以全部杀死癌细胞治愈癌症。”但事实是：“肿瘤病灶里含有多种类型的癌细胞，这些癌细胞还会不断分裂和变化，没有任何一种药物可以杀死所有的癌细胞群。”一个可能你理解不了的事实是：癌细胞能够通过多种办法对治疗药物产生抗性，比如有的癌细胞能进化出一种能力，将进入癌细胞内部的药物给“泵”出去，“您可能会疑惑：癌细胞为何会这么聪明？”其实这是因为在抗癌药的选择压力下，可能999种癌细胞被药物杀死了，恰好有1种癌细胞进化出了“泵”出药物分子的能力而活下来，这个癌细胞随后开枝散叶继续生长和繁殖。今天癌度给大家分享的一篇内容更是毁三观，癌细胞之间能够“友好合作”共享营养物质，对抗生存压力和治疗药物的选择压，这个内容发布在国际著名学术期刊，癌度只是做了相应的编译和整理。参考文献刊例示意图1、癌细胞之间的“友好合作”，这是扯谈的观点吗？竞争不仅仅是存在人类社会，在肿瘤病灶里竞争更加激烈，因为肿瘤细胞增殖速度非常快，导致营养物质一直是处于匮乏状态。抗血管生成药物通过阻断血液供应，进一步加剧了癌细胞之间的竞争。迄今为止，之前研究发现：肿瘤病灶内癌细胞存在竞争关系，竞争营养物质和促进生长的各种因子。单个癌细胞对营养物质的争夺能力确保了该癌细胞生存和开枝散叶的能力。传统观点认为癌细胞是自私自利的，但生态学研究发现：“肿瘤病灶不断变化的生存环境促进了癌细胞之间的协作，而且这个协作涉及到一个名为CNDP2的基因，这个基因有望成为治疗癌症的一个靶点。”协同营养清除机制确保癌细胞在饥饿状态下仍能增殖，并展现其作为靶向治疗的潜力。图：协同营养清除机制确保癌细胞在饥饿状态下仍能增殖，并展现其作为靶向治疗的潜力。当癌细胞缺乏氨基酸谷氨酰胺时，这些癌细胞需要协同才能生存和生长。根据“阿利效应”，不利的生存条件有利于密集的癌细胞群，而不利于稀疏生长的癌细胞群。也就是说严酷的生存条件下单打独斗的癌细胞是会被淘汰的。而癌细胞之间关于营养物质的友好合作就涉及到CNDP2这个基因。竞争性氨基肽酶抑制剂贝他汀（bestatin）治疗可以抑制CNDP2，在体内模型试验显示出抗肿瘤作用。如果添加了额外的谷氨酰胺则药物没有效果了。贝他汀已经在日本获批用于辅助化疗，对于携带KEAP1基因突变肺癌患者尤其有效，因为KEAP1基因突变使得癌细胞更加依赖“合作”对抗营养物质匮乏，当然这个药物还是在比较早期，还没比较大规模应用于临床。2、癌细胞比我们所理解的可怕，怎么办？这篇文章的观点和信息比较多，比较重要的信息是：不同肿瘤细胞群体的相对适应度会随着空间条件（如营养和氧气供应）而变化，癌细胞之间存在竞争也存在合作，这种严酷的生存压力只让那些可塑性很强的癌细胞能存活下来，这些癌细胞会变得越来越难缠、更加具有侵袭性。我们选择这篇内容是希望给大家传递一些知识，避免一些治疗上的误区，比如：已经靶向药耐药的肿瘤，加大药物剂量只会逼迫产生更多数量的超级耐药癌细胞群，因为这将会失去“再挑战”使用靶向药的可能性。如果以自己身体条件好，意志力坚强来面对肿瘤是不够的。五大三粗的大汉子扛不住几个疗程的化疗，咬牙死扛各种不良反应却没有立即癌细胞会进化出将化疗药物给“泵”出去的能力。我们短时间内永远不可能找到一种药物来长期一直将所有癌细胞给压制的死死的，癌细胞是不断变化的，癌细胞之间形成的群体也不断变化。治疗药物和治疗措施也需要不同机制的药物进行轮替、适可而止、巧妙利用癌细胞之间的竞争关系。对新的治疗机制的药物保持热情，即便是处于临床试验阶段的新药物，如果与主要的靶向药，PD-1药物机制不同，就值得去关注和积极使用。不同治疗机制的药物会破坏癌细胞之间的协同和进化，打个措手不及。一直死磕已经耐药的药物加大剂量是没有意义的。最后，希望本文给到大家一些启发，那就是抗击肿瘤的过程是不容易的，不能低估这个过程的艰苦和漫长。但当胜利扛过5年、10年之后，或者您会理解胜利也还是能够被争取、被努力获得的。参考文献：Susanne Sebens, et al., Cancer cell cooperation: tumor cells team up to scavenge nutrients to ensure proliferation despite starvation, Signal Transduction and Targeted Therapy (2025). 往期推荐双靶点埃万妥单抗再立新功，50%的MET基因跳跃突变初治患者病灶大幅度缩小，肠癌和肺癌多项临床研究仍在开展！依沃西单抗肺癌一线适应症获批！全球领先方案，中国患者先用！新数据，阿来替尼联合贝伐单抗治疗ALK阳性肺癌，治疗应答率100%，生存期显著延长！肺癌的二代基因测序都有啥突变？多大比例的患者找到靶向药和临床试验用药机会？

2025-05-21

·ioncology

例例在望丨“钻石恒久远，一颗永流传”——ALK阳性晚期NSCLC治疗的今生今世

点击蓝字关注我们▌马锐，王雪莹丨辽宁省肿瘤医院胸内二科ALK阳性非小细胞肺癌（NSCLC）发生率约为5%-7%，主要分为融合、点突变、扩增突变三种形式，其中ALK融合是ALK+的NSCLC致癌的主要驱动因素，在NSCLC中，以EML4-ALK融合突变为主。EML4-ALK融合有不同的融合亚型，其中以V1和V3a/3b亚型最为常见；ALK的点突变和扩增突变相对少见，通常导致ALK-TKI耐药。ALK基因融合通常出现在较为年轻且非吸烟（或轻度吸烟者）的肺腺癌患者中，ALK-TKI治疗有效率高，生存时间较长，常被称为“钻石突变”。目前ALK-TKI“三代同堂”用于晚期ALK阳性NSCLC的一线治疗，如克唑替尼、塞瑞替尼、阿来替尼、恩沙替尼、布格替尼、洛拉替尼、伊鲁阿克和依奉阿克等。这些ALK-TKI通过抑制ALK融合蛋白磷酸化发挥抗肿瘤作用，约60%-80%的ALK基因融合的NSCLC患者对靶向药敏感，肿瘤显著缩小，同时让很多患者轻松跨越了五年生存大关。ALEX研究表明初治晚期ALK阳性NSCLC患者应用阿来替尼治疗后，中位无进展生存（PFS）长达34.8个月，对比克唑替尼的10.9个月具有显著优势。eXalt 3研究表明恩沙替尼的晚期一线治疗中位PFS达到31.3个月，相较于克唑替尼组的12.7个月有显著延长。CROWN研究结果更为惊艳，一线应用洛拉替尼治疗患者，中位 PFS突破60个月，且5年PFS率高达60%。这彻底改写了ALK基因融合NSCLC的生存预后，让这类患者的“长生存”目标从理想走向现实，让ALK阳性晚期NSCLC的治疗逐步迈入了慢病化时代。现分享2例ALK阳性晚期肺腺癌患者分别在一线及多线应用ALK-TKI治疗病例。马锐教授辽宁省肿瘤医院胸内二科主任，肿瘤学博士中国医科大学、大连医科大学硕士研究生导师学术兼职：中国临床肿瘤学会理事会理事，中国老年学学会老年肿瘤专业委员执行委员，中国老年学学会老年肿瘤专业委员肺癌分委会常务委员，中国医药教育协会肺部肿瘤专委会常务委员，辽宁省生命科学学会常务理事，中国抗癌协会肺癌专业委员会委员，辽宁省抗癌协会理事会理事，辽宁省生命科学学会肺癌专业委员会主任委员，辽宁省抗癌协会肿瘤转移专业委员会主任委员，辽宁省抗癌协会肿瘤标志物专业委员会副主任委员，辽宁省医学会内科学分会委员会常务委员，辽宁省生命科学学会老年肿瘤专业委员会常务委员，沈阳市医学会肺部肿瘤学分会副主委，中国肿瘤生物治疗杂志、中国实用内科、医学与哲学，沈阳医学院学报等多家杂志编委及审稿专家。沈阳市领军人才。主持省部级、市级课题9项，获辽宁省科技进步三等奖2项、沈阳市科技进步二等奖1项，第一及通讯作者发表论文50余篇。王雪莹教授辽宁省肿瘤医院主治医师毕业于中国医科大学附属第一医院硕士研究生学历任职：中国抗癌协会指南专家学术成果：曾在Stem Cells and Regenerative Medicine发表文章病例134岁，女性，无吸烟史饮酒史，既往体健。2015年11月无明显诱因出现咳嗽咳痰，痰为黄色粘液状，就诊于铁西华康医院，胸部CT示右肺上叶尖段可见结节影，邻近胸膜局限牵拉。2015年12月于胸科医院行肺肿物穿刺活检病理回报为肺腺癌。2015年12月16日全麻下行右肺上叶肺癌根治术及纵隔淋巴结清扫术，术后病理：肺组织中部分脉管内见腺癌组织，断端支气管旁淋巴结内见癌组织，淋巴结中见到转移癌（2/6），未行基因检测。2016年1月复查CT提示支气管截断可见新发小结节，一线治疗采用培美曲塞+DDP方案化疗4周期（培美曲塞 3.36,DDP 480mg）。化疗后复查胸部CT：右肺见不规则结节样影，最大层面大小约19mm * 8mm，较前比较明显增大，疗效评估PD。2017.3-2017.4予单药多西他赛化疗3周期，疗效评估SD。2018年5月末复查CT提示结节较前增大，评效为PD，2018年6-10月予多西他赛+CBP化疗4周期，疗效评估SD。2022年5月患者出现活动后气短，复查胸部CT示右肺膨胀不良；右侧胸腔积液增多。胸腔积液包埋病理示符合肺腺癌细胞。行NGS基因检测：EML4：exon13-ALK:exon20融合。PD-L1（克隆号22C3） TPS<1%。临床诊断：右肺上叶恶性肿瘤rT0N0M1a IVA期（第9版分期）；恶性胸腔积液。诊疗经过：2022年5月始口服克唑替尼3个月，出现肝功能异常（DILI 2级伴临床症状），改用恩沙替尼靶向治疗至今，目前评效为维持PR。恩沙替尼应用期间出现轻度肝功能异常（DILI 1级），对症处理后好转。截止目前PFS 33个月。2018.072022.052022.082023.052024.12病例256岁，女性，无吸烟史饮酒史，既往体健。2023年02月患者体检发现肺占位性病变，胸部增强CT：右肺下叶后基底段结节；右侧锁骨上及纵隔内多发淋巴结肿大。PET-CT：右肺下叶周围型肺癌可能性大；1R、2L、3P、4R、4L及7组淋巴结转移可能性大。2023年02月就诊于本院胸外科行超声胃镜下纵隔肿物穿刺活检术，病理：结合免疫组化，符合肺腺癌。行NGS基因检测：EML4：exon20-ALK:exon20融合。PD-L1（克隆号22C3）TPS=55%。临床诊断：右肺下叶恶性肿瘤cT1bN3M0，IIIB（第9版分期），纵隔淋巴结继发恶性肿瘤，锁骨上淋巴肿继发恶性肿瘤治疗经过：2023年3月27日始行恩沙替尼靶向治疗至今，最佳疗效为PR，末次评效为维持PR。期间出现轻度肝功能异常（DILI 1级），对症处理后好转。截止目前PFS为26个月。2023年2月20日基线检查2024年6月复查PR（最佳疗效）2024年12月复查维持PR2025年3月复查维持PR小结上述2例病例NGS基因检测结果均提示EML4-ALK融合突变，但是应用ALK-TKI治疗时间点却截然不同。第1例病例由于当时检测和治疗费用昂贵的受限，并没有及时进行基因检测。在精准治疗时代，分子诊断已经是必须，各大指南均有推荐。目前基因检测的应用不仅适用于晚期患者治疗前或疾病进展、复发后决策，更已经趋向于术前和术后辅助治疗前决策。由于当时经济因素的局限，上述两例患者应用ALK-TKI治疗的时线上虽有差异，但两者PFS还是令人惊喜的。基于在CROWN研究中展现出的疗效与安全性以及三代TKI进入医保，对于ALK+的晚期NSCLC患者，“3+X”的治疗排兵布阵模式正逐渐更多应用。随着ALK-TKI用药选择逐渐增多，患者的疾病管理模式也正逐步转向“慢病化”管理，在维持高质量生活的基础上，通过规范的诊治，实现与疾病长期共存。“慢病化”全程管理模式确保每一位患者都能在“健康中国2030”的宏伟蓝图中，享受高质量生活带来的无限美好。分子诊断指导晚期肺癌后续治疗，事半功倍。ALK-TKI让“钻石”更加闪耀。参考文献（上下滑动可查看）1. Tony Mok, et al. Patterns of Progression with Lorlatinib and Insights into Subsequent Anticancer Therapy Ef ficacy in Advanced ALK+ NSCLC. 2024 WCLC, MA06.07.2. Bearz A, Bertoli E, et al. EML4-ALK: Update on ALK Inhibitors. Int J Mol Sci. 2025 Jan 1;26(1):308. doi: 10.3390/ijms26010308.3. Hong S,Fang W, Hu Z, et al. A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population [J]. Sci Rep, 2014,4: 7268.4. Mok T, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study[J]. Annals of oncology, 2020, 31(8): 1056-1064.5. Zhou Q. eXalt 3 study: First release of Asian population’s efficacy in ALK-positive non-small cell lung cancer (NSCLC). 2022. Available online: https://www.liangyihui. net/class/102928?6. Solomon BJ, et al. Lorlatinib Versus Crizotinib in Patients with Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes from the Phase III CROWN Study. JCO. 2024: JCO. 24.00581.7. WatanabeS,al.Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501). Cancers (Basel). 2022;15(1):204. Published 2022 Dec 29.8. Li Y, et al. Alectinib continuation beyond progression in ALK-positive non-small cell lung cancer with alectinib-refractory. Transl Lung Cancer Res. 2024;13(1):152-1629. Benjamin J Solomon, Tony Mok, Dong-Wan Kim, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer.[J] . 2014 Dec 4;371(23):2167-77.10. Zheng J, et al. Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study. Cancer Commun (Lond). 2024 Apr;44(4):455-468.11. WatanabeS,al.Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501). Cancers (Basel). 2022;15(1):204. Published 2022 Dec 29.12. Xing P, Hao X, Zhang X, Li J. Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis. Front Oncol. 2022;12:920709. Published 2022 Nov 3. doi:10.3389/fonc.2022.920709（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

CSCO会议临床结果高管变更

100 项与盐酸阿来替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10450	盐酸阿来替尼	L01XE	DB11363

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
可切除非小细胞肺癌	欧盟	Roche Registration GmbH	2024-06-19
可切除非小细胞肺癌	冰岛	Roche Registration GmbH	2024-06-19
可切除非小细胞肺癌	列支敦士登	Roche Registration GmbH	2024-06-19
可切除非小细胞肺癌	挪威	Roche Registration GmbH	2024-06-19
晚期非小细胞肺癌	欧盟	Roche Registration GmbH	2017-02-16
晚期非小细胞肺癌	冰岛	Roche Registration GmbH	2017-02-16
晚期非小细胞肺癌	列支敦士登	Roche Registration GmbH	2017-02-16
晚期非小细胞肺癌	挪威	Roche Registration GmbH	2017-02-16
非小细胞肺癌	加拿大	Hoffmann-La Roche Ltd.	2016-09-29
ALK阳性非小细胞肺癌	日本	Chugai Pharmaceutical Co., Ltd.	2015-09-02

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
ALK阳性实体瘤	临床3期	英国	-	2023-12-18
ALK阳性间变性大细胞淋巴瘤	临床3期	英国	-	2023-12-18
间变性大细胞淋巴瘤	临床3期	英国	-	2023-12-18
血液肿瘤	临床3期	英国	-	2023-12-18
神经母细胞瘤	临床3期	英国	-	2023-12-18
肾细胞癌	临床3期	英国	-	2023-12-18
局部晚期非小细胞肺癌	临床3期	美国	Hoffmann-La Roche, Inc.	2022-11-01
局部晚期非小细胞肺癌	临床3期	中国	Hoffmann-La Roche, Inc.	2022-11-01
局部晚期非小细胞肺癌	临床3期	日本	Hoffmann-La Roche, Inc.	2022-11-01
局部晚期非小细胞肺癌	临床3期	澳大利亚	Hoffmann-La Roche, Inc.	2022-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05015010 (ALNEO, ASCO2025)	临床2期	非小细胞肺癌 III期新辅助 \| 辅助	33	Alectinib	製壓觸鹽襯遞蓋窪憲遞(鹹鏇願遞獵蓋網顧窪繭) = 艱艱築遞繭獵製襯襯簾構襯製鏇餘積繭鑰淵遞 (簾範積憲築願襯蓋構窪, 31% ~ 61) 更多	积极	2025-05-30
NCT04774718 (iMATRIX alectinib, ASCO2025)	临床1/2期	中枢神经系统肿瘤 ALK-fusions	22	Alectinib	製夢鏇繭蓋觸鹹鹽廠積(廠鏇鹽衊製鬱網齋壓鹽) = Eighteen patients (86%) experienced at least one Adverse Event (AE) reported as related to Alectinib, the majority being of Grade 1 and 2 severity. 願鬱顧齋獵鬱鑰鬱艱糧 (繭衊醖鬱醖選衊鏇餘範 ) 更多	积极	2025-05-30
ASCO2025	N/A	ALK阳性非小细胞肺癌 Anaplastic lymphoma kinase (ALK)-positive	306	Alectinib 300 mg b.i.d.	繭製積淵鹹積糧鬱願憲(築壓齋鹹壓齋衊餘襯顧) = the 600 mg group showed more frequent adverse events than the 300 mg group and required dose reduction in 137 patients (50%) 蓋構網選觸齋鹹繭艱顧 (繭願構醖獵簾夢鹹鏇積 ) 更多	积极	2025-05-30
ASCO2025	N/A	ALK阳性非小细胞肺癌 Anaplastic lymphoma kinase (ALK)-positive	306	Alectinib 600 mg b.i.d.		积极	2025-05-30
JPRN-jRCT2091220364 (TACKLE phase II trial, ASCO2025)	临床2期	晚期恶性实体瘤 fusion/rearrangements \| mutations \| amplifications	26	Alectinib	築憲積選膚衊鬱淵築顧(糧築壓艱壓膚鏇憲糧鹽) = 積鑰糧範選糧憲憲蓋齋鏇遞選顧窪鑰醖憲壓積 (壓淵蓋艱鬱繭積壓夢衊, 32.8 ~ 74.4) 更多	积极	2025-05-30
NCT03779191 (ALEK-B, Pubmed) 人工标引	临床2期	ALK阳性非小细胞肺癌一线 ALK Rearrangement	41	Alectinib 600 mg BID + Bevacizumab 15 mg/kg	獵築鹹鏇鹽製糧製膚願(簾襯顧淵鏇築積製觸積) = 蓋積鹽醖願遞夢鹹觸壓鹹鏇顧構壓鹽鑰鑰衊膚 (夢積製鏇憲鑰製遞糧簾, 92.6 ~ 100) 更多	积极	2025-05-16
NCT02521051 (CTgov)	临床1/2期	ALK阳性非小细胞肺癌	11	Alectinib+Bevacizumab (Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg)	鹹廠繭構壓夢齋構顧蓋 = 鹹夢齋簾鑰範選顧膚鏇齋網醖築範製艱製鏇願 (鏇遞糧壓鏇簾範鑰製願, 積鏇選糧壓夢襯廠鬱窪 ~ 鑰艱艱顧製鬱夢衊網窪) 更多	-	2025-05-13
NCT02521051 (CTgov)	临床1/2期	ALK阳性非小细胞肺癌	11	Alectinib+Bevacizumab (Phase II: RP2D)	糧衊鬱醖築壓顧壓網遞 = 鏇淵憲範願齋醖淵遞齋襯鹽壓繭醖夢鏇遞鬱鬱 (顧糧願選範襯糧製鑰夢, 網蓋壓夢衊齋範艱蓋鬱 ~ 鏇遞選顧餘壓齋憲遞鏇) 更多	-	2025-05-13
ESMO_ELCC2025	N/A	ALK阳性肺癌新辅助 ALK rearrangement	9	Neoadjuvant Alectinib	鹽簾積獵遞觸廠餘觸糧(糧襯齋構顧窪構積顧膚) = 遞憲鑰積遞顧衊糧遞鑰網淵窪顧醖顧齋衊鹹憲 (憲範獵顧遞獵鏇網鏇鑰 ) 更多	积极	2025-03-26
NCT03445000 (ALERT-lung, CTgov)	临床2期	转移性非小细胞肺癌 \| 晚期非小细胞肺癌 \| 复发性非小细胞肺癌	14	Alectinib	範醖憲遞簾鹽餘衊鑰繭 = 簾衊願遞觸繭壓築遞製壓鹽壓夢鏇窪衊積獵顧 (衊艱鏇願鬱廠繭鬱觸獵, 憲鑰壓築觸糧蓋積選鬱 ~ 選餘選淵鑰窪繭膚鑰選) 更多	-	2025-03-26
NCT02075840 \| NCT02604342 \| NCT02271139 (pooled analysis of individual patient data from four clinical trials, Pubmed \| J Clin Oncol)	临床3期	ALK阳性非小细胞肺癌	302	Alectinib	選鑰鑰鹽選壓簾顧製選(膚艱壓艱遞齋廠艱鬱鑰) = Actual weight gain of any grade was substantially higher than reported AE rates (49% v 5%), with 18% experiencing ≥10% weight gain (from median 55.6 kg to 64.1 kg) 齋顧廠醖鬱餘醖鹽積齋 (遞選夢選鹽膚鬱衊顧製 )	积极	2025-02-20
ESMO2024 人工标引	N/A	ALK阳性非小细胞肺癌一线	382	Alectinib	衊構選糧範餘憲範積鏇(壓醖壓願齋觸鬱構獵積) = 鹽蓋衊網襯淵鹽膚鑰齋遞顧襯憲選簾鏇膚夢淵 (築艱艱選願遞願遞鏇網 ) 更多	积极	2024-09-14
ESMO2024 人工标引	N/A	ALK阳性非小细胞肺癌一线	382	Alectinib (baseline brain metastases)	夢廠衊遞壓網選膚繭選(簾簾範艱繭網餘獵鏇鬱) = 獵艱構遞鬱構製構廠鬱鏇糧積襯憲鑰鏇鹽糧願 (壓願壓範鹽簾夢壓願構 ) 更多	积极	2024-09-14